AstraZeneca, AVEO Oncology form lung cancer collaboration
AVEO Oncology has announced the start of an immuno-oncology focused clinical collaboration with drug giant AstraZeneca (AZ).
Read More
Tag: Fotivda
Three cancer treatments approved for use on NHS Scotland
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the SMC.
Read More
NICE backs EUSA’s kidney cancer drug Fotivda
The National Institute for Health and Care Excellence (NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option for advanced renal cell carcinoma.
Read More
EUSA bags EU approval for kidney cancer drug
The European Commission has licensed EUSA Pharma’s Fotivda for the management of adult patients with advanced kidney cancer across the European Union as well as Norway and Iceland.
Read More
NICE turns down kidney cancer drugs
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Read More
EMA advisors back eight medicines for approval
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
